drugset
drugset / Trial / NCT03338556

A Study to Examine the Duration of Effect of PrEP-001 in Healthy Subjects Challenged With HRV-16

NCT03338556 ↗

Phase 2 Completed 102 enrolled Prep Biopharm Limited Hvivo · collab
RandomizedParallel-groupQuadruple-blindPrevention

Summary

A study to examine the duration of effect of PrEP-001 in healthy subjects challenged with HRV-16

Timeline

Start
2016-04-06
Primary completion
2016-09-30
Completion
2016-09-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator PrEP-001 Unknown 6400 ug Intranasal

Indications

viral respiratory tract infection